LATEST NEWS

CHEETAH MEDICAL SECURES $5 MILLION INVESTMENT FROM HIGHCAPE PARTNERS

NEWTON, Mass., June 6th, 2014 — Cheetah Medical, Inc., a leader in non-invasive hemodynamic monitoring systems, today announced that it has secured an initial investment of $5 million from HighCape Partners, a firm co-founded by Kevin Rakin, who joined Cheetah Medical’s Board of Directors in 2013. HighCape is a growth equity firm with a specialized focus and partner expertise in transforming commercial-stage life sciences companies into sustainable businesses. This investment from HighCape is an extension of the previously announced $9 million fundraising round, which closed in February 2014.

Cheetah Medical, headquartered in Newton Center, MA, has developed the CHEETAH NICOM Hemodynamic Management System. Based on the Company’s proprietary bioreactance technology, the CHEETAH NICOM offers a completely non-invasive means to measure key hemodynamic parameters. The system is currently available in more than 60 countries, including the United States.

Kevin Rakin, Founding Partner of HighCape Partners commented, “For the past year, I have had the opportunity as a board member to watch the Company develop and grow. Based on this experience, we believe that the CHEETAH NICOM technology has the potential to address the unmet need for better patient monitoring technologies, and that management’s current commercialization strategy has the Company poised for success.”

Stephen Reeders, Chairman of Cheetah Medical Inc. and founder of MVM Life Science Partners added, “We remain enthusiastic about the quality of and opportunity for Cheetah’s technology to improve patient outcomes. Kevin and the HighCape team have a track record of successfully identifying, investing in and transforming commercial stage companies into scalable, revenue-generating entities, and we believe their expertise will enhance our collective efforts to make the CHEETAH NICOM a standard of care.”

“We believe that our technology has the potential to bring significant value to clinicians and other healthcare providers in the ICU, operating room and emergency department by driving fundamental improvements in patient monitoring. This additional capital will fund the continued expansion of our sales and marketing activities in the U.S. and internationally. We are grateful for the continued support of our investors and excited to add HighCape to that list.” said Chris Hutchison, President and CEO of Cheetah Medical.

Mr. Hutchison joined Cheetah Medical in March of 2013 and has recruited key management talent with experience from such world class companies as from Boston Scientific, Covidien, Smiths Medical and Bard.

About Cheetah Medical

Cheetah Medical, Inc. is a global leader in non-invasive hemodynamic monitoring. Cheetah Medical manufactures and commercializes the CHEETAH NICOM Hemodynamic Management System which offers innovative solutions to inform better clinical decision making. Available in more than 60 countries, the CHEETAH NICOM Hemodynamic Management System delivers value through its unique clinical and health economic advantages. To learn more about Cheetah Medical and the CHEETAH NICOM, please visit www.cheetah-medical.com

LATEST NEWS

CHEETAH MEDICAL SECURES $5 MILLION INVESTMENT FROM HIGHCAPE PARTNERS

BioEnvelope Reduces Scarring, Improves Device Stability

LAKE OSWEGO, Ore. and SILVER SPRING, Md., April 3, 2018 /PRNewswire/ — BIOTRONIK US and Aziyo today announced a strategic agreement allowing BIOTRONIK to distribute Aziyo’s CanGaroo® extracellular matrix (ECM) cardiovascular implantable electronic device (CIED) envelopes in the United States. BioEnvelope will be available from BIOTRONIK starting in April 2018.

BioEnvelope’s unique ECM material consists of a flexible bioscaffold that remodels in three to six months while encouraging the body to naturally regrow and restore functional, vascularized tissue. (PRNewsfoto/BIOTRONIK)

BioEnvelope’s unique ECM material consists of a flexible bioscaffold that remodels in three to six months while encouraging the body to naturally regrow and restore functional, vascularized tissue.
BioEnvelope reduces scar formation and has been shown to mitigate the risk of device migration and erosion in in vivostudies.1 Its unique ECM material consists of a flexible bioscaffold that remodels in three to six months while encouraging the body to naturally regrow and restore functional, vascularized tissue. The newly remodeled tissue may enhance patient comfort and facilitate easier CIED removal for future device replacements.

Device dislodgement and pocket infection following implantation are serious complications that are associated with higher mortality and increased healthcare costs.2 BIOTRONIK partners with hospitals and health systems to alleviate the cost burden of long-term care for CIED patients.

“At BIOTRONIK, quality patient outcomes are our utmost priority. Our parternships with hospitals to reduce cost exemplify our commitment to value-based care,” said Marlou Janssen, President of BIOTRONIK, Inc. “That is why our partnership with Aziyo, a proven regenerative medicine company, is so important. It’s a partnership that will significantly improve patient care.”

With BioEnvelope, physicians can choose how to best treat each individual patient with or without local antibiotic use, extending the benefits of CIED envelopes to more patients and further customizing care.

“It’s an exciting time to embrace the merging fields of regenerative medicine and cardiac rhythm management,” said Dr. John N. Catanzaro, FESC, FACC, FHRS, SECURE study investigator, associate medical director and associate program director of electrophysiology in Jacksonville, Florida. “The natural ECM material benefits our patients by promoting a natural healing environment that produces a healthy, vascularized tissue pocket without inflammation, scarring or calcification.”

BioEnvelope is indicated for use with the full spectrum of transvenous and subcutaneous CIEDs and has a three-year shelf life. It is also made in five sizes, eliminating the need to manually resize envelopes on a case-by-case basis.

“BIOTRONIK is trusted and respected by hospitals, physicians and patients, and our distribution partnership expands access to a meaningful cardiovascular solution,” said Andrew Green, Aziyo’s EVP and General Manager of Cardiovascular Products. “Our ECM envelopes help deliver the best possible patient care and can reduce cost, providing advantages that complement BIOTRONIK’s comprehensive portfolio of cardiac rhythm management devices. This partnership changes the landscape of cardiac care.”
References:

  1. Data on file.
  2. Polyzos K et al. EP Europace. 2015, 17(5).


About BIOTRONIK
BIOTRONIK is a leading medical device company headquartered in Berlin, Germany, and represented in over 100 countries. Our products save and improve the lives of millions of patients with heart and blood vessel diseases every year. Since developing the first German pacemaker in 1963, BIOTRONIK continues to innovate cardiovascular and endovascular services and solutions. BIOTRONIK has US offices in Lake Oswego, Oregon and New York City.

About Aziyo Biologics, Inc.
Aziyo Biologics is a fully integrated, commercially oriented regenerative medicine company. Since its founding in 2015, the company has expanded through acquisitions and strategic partnerships, creating a high-growth commercial entity. Its proprietary products are used in orthopedic, cardiovascular and other medical specialties.

For more information, visit: www.biotronik.com
Connect on Facebook , Twitter , LinkedIn and YouTube.

SOURCE BIOTRONIK

Related Links
http://www.biotronik.com

CONTACT US

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed laoreet velit mauris, vel condimentum lorem porttitor in. Nunc vehicula luctus ante eget posuere.